相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
Zsofia K. Stadler et al.
CANCER (2012)
Synthetic Lethality to Overcome Cancer Drug Resistance
L. Porcelli et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Combined modality treatments in pancreatic cancer
Lucia Lombardi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699
J. E. Hunter et al.
ONCOGENE (2012)
BRCAness: Finding the Achilles Heel in Ovarian Cancer
Georgios Rigakos et al.
ONCOLOGIST (2012)
Genomics and pharmacogenomics of pancreatic adenocarcinoma
M. A. Lowery et al.
PHARMACOGENOMICS JOURNAL (2012)
The clinical development of inhibitors of poly(ADP-ribose) polymerase
H. Calvert et al.
ANNALS OF ONCOLOGY (2011)
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
A. Azzariti et al.
BRITISH JOURNAL OF CANCER (2011)
How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation
Aswin Mangerich et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Yvette Drew et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
Majid Ali et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: A meta-analysis
Chang-Peng Zhu et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective
Marcel Verheij et al.
DRUG RESISTANCE UPDATES (2010)
Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets
Anthony J. Chalmers et al.
SEMINARS IN RADIATION ONCOLOGY (2010)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma
Geertjan van Tienhoven et al.
Therapeutic Advances in Medical Oncology (2010)
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?
Majid Ali et al.
CLINICAL CANCER RESEARCH (2009)
Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression
Shauna A. Lee et al.
DNA REPAIR (2009)
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms
Jie Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
NEOADJUVANT RADIATION IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH RESECTABLE PANCREATIC CANCER: AN ANALYSIS OF DATA FROM THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) REGISTRY
Alexander M. Stessin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation - Long-term results of EORTC trial 40891
Hans G. Smeenk et al.
ANNALS OF SURGERY (2007)
Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO)
Thomas B. Brunner et al.
BMC CANCER (2007)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Cytokinesis-block micronucleus cytome assay
Michael Fenech
NATURE PROTOCOLS (2007)
Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer
Amalia Azzariti et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Value of CT criteria in predicting survival in patients with potentially resectable pancreatic head carcinoma
SSKS Phoa et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Recovery from DNA damage-induced G2 arrest requires actin-binding protein filamin-A/actin-binding protein 280
XB Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa,™, ZD1839)
A Azzariti et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Characteristics of γ-H2AX foci at DNA double strand breaks sites
DR Pilch et al.
BIOCHEMISTRY AND CELL BIOLOGY (2003)
分享论文
